To determine whether newly developed treatments are safe and effective, physician-scientists rely on clinical trials. These studies are not only important research tools; they also provide patients with access to experimental therapies not yet widely available.
Because technologies and therapeutic options are continually developing, the OMRF Multiple Sclerosis Center uses clinical trials as one way of delivering cutting-edge treatments to our patients. Of course, participating in clinical trials is optional. But many choose to enroll to receive new therapies and improve standards of care for individuals with MS. Patients also receive medication, laboratory and diagnostic procedures, and intensive medical evaluation and assessment—all at no cost.
Patients may also participate in our MS Center Registry and Repository. This unique research tool allows individuals with MS to provide clinical information and samples to help our physician-scientists better understand this complicated disease.
Clinical research is proving that with comprehensive disease management, we can impact the course of the disease, achieve normal or near-normal life expectancy, reduce the potential for significant disability, and improve quality of life.
For more information on any of our studies, call (405) 271-6241 or email Mickifirstname.lastname@example.org.
A Prospective, Multicenter, Observational, Post-authorization Safety Study (PASS) to Evaluate the Long Term Safety Profile of LEMTRADA® (alemtuzumab) Treatment in Patients with Relapsing Forms of Multiple Sclerosis,” Protocol OBS13434
A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate,” Protocol ALK8700-A302
Multi-center, Randomized, Double-blinded Assessment of Tecfidera® in Extending the Time to a First Attack in Radiologically Isolated Syndrome (RIS) (ARISE)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies, the AFFINITY Study” protocol 215MS202
A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients with Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers after Treatment with 0.5 mg Fingolimod (FLUENT),” Protocol CFTY720DUS4